SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Synsorb Biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fred J Bealle who wrote ()3/7/1997 1:29:00 PM
From: Fred J Bealle   of 32
 
Excuse this late posting of STockwatch news on Syb; $700 000 from nserc. I despise subsidies, but at least this one went to a good cause. Here is the text.
Fred
Synsorb Biotech Inc - News Release

Research agreement to finance investigation of new methods of
carbohydrate synthesis

Synsorb Biotech Inc
SYB
Shares issued 16084520
1997-03-03 close $10.25
Tuesday Mar 4 1997
News Release
Mr David Rafter reports
The company has finalized a collaborative research agreement between with the University
of Alberta and the joint NRC/NSERC Research Partnership Program created by the Natural
Sciences and Engineering Research Council of Canada (NSERC) and the National Research
Council of Canada (NRC).
The NRC/NSERC Research Partnership Program provides financing to universities for
research that involves collaboration with NRC institutes and companies in the private sector.
As the industry sponsor of the project, the company will receive access to any research data
generated by the project.
A research team led by Dr Monica Palcic of the University of Alberta will receive $701,100 for
a three year study of alternative methods for the synthesis of clinically-relevant
carbohydrates as anti-infective agents. The research group will investigate new and cost
effective methods of enzymatically synthesizing carbohydrates suitable for commercial
scale-up. Specific disease targets for the project include rotavirus, the leading cause of viral
diarrhea in children, as well as additional bacterial and viral conditions.
Improved methods of carbohydrate synthesis will greatly enhance the company's ability to
develop new carbohydrate-based drugs. The company is currently investigating the use of
carbohydrate-based pharmaceuticals for the treatment of toxin-mediated bacterial infections.
(c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News